SB 460 - Under this act, collaborative practice arrangements may be entered into by a physician and an advanced practice registered nurse (APRN) in any county except Kansas City, Springfield, Columbia, St. Louis, and St. Louis City.
An APRN may be delegated the authority to administer, dispense, or prescribe controlled substances listed in Schedules III, IV, and V, and Schedule II -Hydrocodone so long as such APRN has been granted a certificate of controlled substance prescriptive authority.
Current law grants authority to the State Board of Registration for the Healing Arts and the Board of Nursing to jointly promulgate rules regulating the use of collaborative practice arrangements. Such rules are required to be limited to specifying geographical areas to be covered, the methods of treatment that may be covered by collaborative practice arrangements, and the requirements for review of services including delegating authority to prescribe controlled substances. This act repeals such provision, and requires the rules promulgated by the State Board and the Board to be limited to delegating authority to prescribe controlled substances. Any previously adopted rules that are not limited to delegating authority to prescribe shall be null and void upon the effective date of this act.
Currently, the State Board may make certain information regarding collaborative practice arrangements available to the public. This act requires the Board to make such information public.
Current law prohibits a collaborating physician from entering into a collaborative practice arrangement with more than six full-time APRNs, physician assistants, or physicians, and requires the collaborating physician to determine and document the completion of a one-month period of time during which the APRN shall practice with the collaborating physicians. Current law also prohibits an agreement from limiting the collaborating physician's authority over protocols or standing orders. This act repeals such provisions. (Section 334.104)
This act defines an APRN as a person who is licensed to engage in the practice of advanced practice nursing in one of the four APRN roles, including a certified clinical nurse specialist, a certified nurse midwife, a certified nurse anaesthetist, and a certified nurse practitioner.
The practice of professional nursing shall include elements set forth in the act, including the authority to prescribe, order, procure, administer, dispense, and furnish controlled substances listed in Schedules III, IV, and V, and Schedule II-Hydrocodone as part of a collaborative practice arrangement.
APRNs are required to wear identification that clearly identifies the nurse as an APRN when providing direct patient care. (Section 335.016)
Under this act, an APRN's prescriptive authority shall include the authority to prescribe, dispense, and administer nonscheduled legend drugs and medications, and receive, prescribe, administer, and provide nonscheduled legend drug samples from pharmaceutical manufacturers to patients at no charge to the patient or any other party.
Current law allows the Board of Nursing to grant a certificate of controlled substance prescriptive authority to an APRN who meets certain requirements, including proof of successful completion of an advanced pharmacology course that shall include preceptorial experience in the prescription of drugs. This act removes the requirement that the APRN have preceptorial experience in the prescription of drugs.
The certificate of controlled substance prescriptive authority may be granted to an APRN to administer, dispense or prescribe controlled substances listed in Schedules III, IV, and V and Schedule II-Hyrdocodone, except the APRN shall not administer any controlled substances for the purpose of inducing sedation or general anaesthesia for therapeutic, diagnostic, or surgical procedures. (Section 335.019)
An applicant for a license to practice as an APRN is required to submit a completed application, which must contain certain information set forth in the act. (Section 335.046)
This act is similar to SCS/SB 400 (2019), SCS/HCS/HB 301 (2019), HB 693 (2019), and SCS/SB 705 (2019).